Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity

Masayoshi Harigai, Tsutomu Takeuchi, Yoshiya Tanaka, Tsukasa Matsubara, Hisashi Yamanaka, Nobuyuki Miyasaka

Research output: Contribution to journalArticlepeer-review

34 Citations (Scopus)


Objective We implemented a retrospective study to explore discontinuation of therapy with adalimumab (ADA) without exacerbation in rheumatoid arthritis (RA) patients who had achieved low disease activity (LDA) with the biological agent. Methods We enrolled 46 RA patients who had completed open extension of a double-blind, placebo-controlled trial of ADA monotherapy in Japan and who had LDA (DAS28- CRP <2.7) at the last administration of ADA in the extension trials; this date was defined as week 0 in the present study. Treatment of RA was at the discretion of the attending physician after week 0. The primary endpoint of this study was the percentage of patients who maintained discontinuation of biological agents and LDA for 52 weeks. Results Twenty-four of the enrolled patients continued ADA while the rest discontinued ADA after the administration of the drug at week 0. Fourteen of the 22 patients did not restart biological agents, and 4 (18.2%) of these maintained LDA through week 52. All 4 of these patients had received ADA monotherapy before week 0. Conclusion Some RA patients who have achieved LDA with ADA monotherapy can discontinue the biologic without incurring increased disease activity. A prospective randomized study is required to confirm the results of our study.

Original languageEnglish
Pages (from-to)814-822
Number of pages9
JournalModern rheumatology
Issue number6
Publication statusPublished - 2012 Nov


  • Adalimumab
  • Biological disease-modifying antirheumatic drug
  • Low disease activity
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity'. Together they form a unique fingerprint.

Cite this